Maria Τektonidou/LinkedIn
Apr 2, 2026, 14:39
Maria Τektonidou: STAT1 as a Potential Therapeutic Target in Thrombotic Antiphospholipid Syndrome
Maria Τektonidou, Professor of Rheumatology at National and Kapodistrian University of Athens, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, adding:
“Gene co-expression and drug-gene interaction analysis reveal STAT1 as a potential therapeutic target in thrombotic antiphospholipid syndrome”
Title: RNA sequencing-derived gene co-expression and drug-gene interaction analysis reveal STAT1 as a potential therapeutic target in thrombotic antiphospholipid syndrome
Authors: Michail Baltsiotis, Kleio-Maria Verrou, Petros P Sfikakis, Maria G Tektonidou
Read the Full Article on Frontiers in Immunology
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 25, 2026, 00:07Muhammad Ali Khan: Using EHR Data to Predict Fibrotic Progression in PV and ET
-
Aug 25, 2026, 00:06Michael R. Scoma: The Vascular Dimension of Long COVID
-
Aug 24, 2026, 23:40Vimee Bindra: Your Period May Be Trying to Tell You Something
-
Aug 24, 2026, 23:30R. P. Singh: Hemophilia and HIV Relationship
-
Aug 24, 2026, 23:12Marta Velia Antonini: Hemolysis in ECMO – More Than Just a Laboratory Finding
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada